INS and metabolic disease: After 12 weeks of treatment, compared to baseline, GLP-1 RA+Met showed more robust improvement than baseline on metabolic disorders, such as glucose metabolism (e.g., decreased HbA1c, FBG、AUC-INS, FINS level, OGTT-120 min, 180 min and HOMA-IR), lipid metabolism (e.g., decreased TC and LDL), and inflammatory markers (e.g., decreased Interleukin 6 (IL-6) levels), (P < 0.05 or P < 0.01) (Table 1, Fig. 3 I-M).